scholarly journals The potential diagnosis role of TP53 mutation in advanced bladder cancer: A meta‐analysis

2021 ◽  
Author(s):  
Yihao Liao ◽  
Huiqin Tang ◽  
Miaomiao Wang ◽  
Keke Wang ◽  
Youzhi Wang ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Tp53 Mutation ◽  
Meta Analysis ◽  
Advanced Bladder Cancer

The role of enfortumab vedotin and sacituzumab govitecan in treatment of advanced bladder cancer

2021 ◽  
Author(s):  
Kirollos S Hanna ◽  
Samantha Larson ◽  
Jenny Nguyen ◽  
Jenna Boudreau ◽  
Jennifer Bulin ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Immune Checkpoint ◽  
Checkpoint Inhibitors ◽  
Second Line ◽  
Antibody Drug Conjugate ◽  
Drug Conjugates ◽  
Advanced Bladder Cancer ◽  
Checkpoint Inhibitor Therapy ◽  
Antibody Drug

Abstract Disclaimer In an effort to expedite the publication of articles pandemic, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time. Purpose The treatment landscape of advanced bladder cancer continues to evolve with novel therapeutics approved in recent years and many in the pipeline. Here we review the role of the novel agents enfortumab vedotin and sacituzumab govitecan in treatment of advanced disease. Summary Patients with advanced bladder cancer often first receive platinum-based therapy, while immune checkpoint inhibitors offer a maintenance option following cytotoxic chemotherapy or a second-line option. Despite various first- and second-line options, patients with significant comorbidities and treatment-related adverse events will experience disease progression requiring alternative treatment. Enfortumab vedotin and sacituzumab govitecan are novel antibody-drug conjugates approved in patients with advanced bladder cancer following platinum-based and immune checkpoint inhibitor therapy. Following platinum-based therapy and immunotherapy in patients with advanced bladder cancer, enfortumab vedotin, targeting Nectin-4, improves overall survival while sacituzumab govitecan, targeting Trop-2, is associated with a 27% response rate. With these new approaches to disease management, however, it remains critical to understand safety, efficacy, and operational considerations to optimize outcomes. Conclusion When selecting an antibody-drug conjugate to treat patients with bladder cancer, it is important to note the adverse event profile of each agent to optimize outcomes and safety for patients.

Neoadjuvant Chemotherapy Plus Cystectomy Compared With Cystectomy Alone for Locally Advanced Bladder Cancer

2021 ◽  
pp. 141-146
Author(s):  
Vikram M. Narayan
Keyword(s):  
Adverse Effect ◽  
Overall Survival ◽  
Bladder Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Randomized Study ◽  
Locally Advanced ◽  
Common Adverse Effect ◽  
Advanced Bladder Cancer ◽  
Muscle Invasive

This study summarizes a landmark study on the role of neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) in patients with muscle-invasive bladder cancer. This randomized study of M-VAC plus cystectomy versus cystectomy alone suggested improved overall survival in patients receiving neoadjuvant therapy. Severe granulocytopenia was a common adverse effect in the chemotherapy group, but no deaths were attributed to chemotherapy.

Role of urinary tract infection in bladder cancer: a systematic review and meta-analysis

2018 ◽  
Vol 36 (8) ◽  
pp. 1181-1190 ◽  
Author(s):  
Christopher E. Bayne ◽  
Dannah Farah ◽  
Katherine W. Herbst ◽  
Michael H. Hsieh
Keyword(s):  
Systematic Review ◽  
Bladder Cancer ◽  
Urinary Tract Infection ◽  
Urinary Tract ◽  
Tract Infection ◽  
Meta Analysis

Phase I/II trial for evaluation of the role of gemcitabine as a radiosensitizer in locally advanced bladder cancer in Egypt

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 4727-4727
Author(s):  
A. O. Abd-Elghany ◽  
H. T. Kamal ◽  
K. A. El Ghamrawy ◽  
Y. Gouda ◽  
W. O. Arafat
Keyword(s):  
Bladder Cancer ◽  
Phase I ◽  
Locally Advanced ◽  
Advanced Bladder Cancer

Role of Restaging Transurethral Resection for T1 Non–muscle invasive Bladder Cancer: A Systematic Review and Meta-analysis

2018 ◽  
Vol 4 (4) ◽  
pp. 558-567 ◽  
Author(s):  
Angelo Naselli ◽  
Rodolfo Hurle ◽  
Stefano Paparella ◽  
Nicolò Maria Buffi ◽  
Giovanni Lughezzani ◽  
...  
Keyword(s):  
Systematic Review ◽  
Bladder Cancer ◽  
Transurethral Resection ◽  
Meta Analysis ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive

scholarly journals Prognostic Role of Survivin in Bladder Cancer: A Systematic Review and Meta-Analysis

PLoS ONE ◽  
2013 ◽  
Vol 8 (10) ◽  
pp. e76719 ◽  
Author(s):  
Chanhoo Jeon ◽  
Myong Kim ◽  
Cheol Kwak ◽  
Hyeon Hoe Kim ◽  
Ja Hyeon Ku
Keyword(s):  
Systematic Review ◽  
Bladder Cancer ◽  
Meta Analysis ◽  
Prognostic Role
Sign in / Sign up

Export Citation Format

Share Document